Back
Ceriani_2022_MDPI_cancers
Journal article

Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients : a post hoc analysis of the SAKK38/07 study

  • Genta, Sofia Clinic of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Ghilardi, Guido ORCID Clinic of Hematology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Cascione, Luciano ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland ; Swiss Institute of Bioinformatics, Lausanne, Switzerland
  • Juskevicius, Darius ORCID Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
  • Tzankov, Alexandar ORCID Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
  • Schär, Sämi Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland
  • Milan, Lisa Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
  • Pirosa, Maria Cristina Clinic of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland ; Clinic of Hematology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Esposito, Fabiana Clinic of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Ruberto, Teresa Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
  • Giovanella, Luca ORCID Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland ; Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland
  • Hayoz, Stefanie Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland
  • Mamot, Christoph ORCID Division of Oncology, Cantonal Hospital Aarau, Aarau, Switzerland
  • Dirnhofer, Stefan Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
  • Zucca, Emanuele ORCID Clinic of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland ; Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland ; Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland
  • Ceriani, Luca ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland ; Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Show more…
  • 2022
Published in:
  • Cancers. - 2022, vol. 14, p. 1018
PET/CT
Mutational profile
DLBCL
Lymphoma
Prognostic index
English Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated SOCS1 with wild-type CREBBP and EP300 defined a group of patients with a favorable prognosis and 2-year progression-free survival (PFS) of 100%. Using an unsupervised recursive partitioning approach, we generated a classification-tree algorithm that predicts treatment outcomes. Patients with elevated metabolic tumor volume (MTV) and high metabolic heterogeneity (MH) (15%) had the highest risk of relapse. Patients with low MTV and favorable mutational profile (9%) had the lowest risk, while the remaining patients constituted the intermediate-risk group (76%). The resulting model stratified patients among three groups with 2-year PFS of 100%, 82%, and 42%, respectively (p < 0.001).
Collections
Language
  • English
Classification
Medicine
License
CC BY
Open access status
gold
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1326726
Statistics
Document views: 14 File downloads:
  • Ceriani_2022_MDPI_cancers.pdf: 35